Metrics as of 10/15/2026, 08:27 AM (Berlin time), refresh in progress.
BriaCell Therapeutics Stock
BriaCell Therapeutics Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- William V. Williams
- Employees
- 16
- Market cap
- $32 M
- IPO
- 14/03/2012
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized…
BriaCell Therapeutics stock: price history
1D
-0.5%
1W
-7.8%
1M
+3.7%
6M
-20.1%
YTD
-48.1%
1Y
-67.7%
2Y
-97.3%
5Y
-99.7%
10Y
-99.9%
Next earnings date
Next earnings date
No date known
Volatility around earnings
~27% weaker price swings than usual
Ask the agents about BriaCell Therapeutics
Analyst assessment of BriaCell Therapeutics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 27/08/2025
BriaCell Therapeutics stock metrics
P/E
-0.3
P/B
1.11
EV/EBITDA
-0.8
RETURN ON EQUITY
-29.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/04/2026
Free float & liquidity
FREE FLOAT
90.3%
FLOAT SHARES
7,859,562
AVG. DAILY VOLUME (30D)
120,547
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BriaCell Therapeutics stock
What does BriaCell Therapeutics do?
BriaCell Therapeutics Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is William V. Williams, the company employs around 16 people.
The IPO was on 14/03/2012; the stock trades on NASDAQ under the ticker BCTX.
What do analysts say about BriaCell Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 27/08/2025).
This is an external assessment, not a statement by Market Jury.
When does BriaCell Therapeutics report next?
Around past earnings, price swings were roughly -27% stronger than usual.
Does BriaCell Therapeutics pay a dividend?
No, BriaCell Therapeutics currently does not pay a dividend.
Which stocks are comparable to BriaCell Therapeutics?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get BriaCell Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess BriaCell Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.